当前位置: X-MOL 学术ACS Pharmacol. Transl. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
ACS Pharmacology & Translational Science Pub Date : 2020-08-04 , DOI: 10.1021/acsptsci.0c00093
Biplab K Maiti 1
Affiliation  

SARS-CoV-2 encoded papain-like protease (PLpro) harbors a labile Zn site (Cys189–X–X–Cys192–Xn–Cys224–X–Cys226) and a classic catalytic site (Cys111–His272–Asp286), which play key roles for viral replication and hence represent promising drug targets. In this Viewpoint, both sulfur-based drugs and peptides-based inhibitors may block Cys residues in the catalytic and/or Zn site of CoV-2-PLpro, leading to dysfunction of CoV-2-PLpro and thereby halting viral replication.

中文翻译:

木瓜蛋白酶样蛋白酶抑制剂能否阻止 SARS-CoV-2 复制?

SARS-CoV-2 编码的木瓜蛋白酶 (PLpro) 具有不稳定的 Zn 位点 (Cys 189 –X–X–Cys 192 –X n –Cys 224 –X–Cys 226 ) 和一个经典的催化位点 (Cys 111 –His) 272 –Asp 286),在病毒复制中发挥关键作用,因此代表了有前途的药物靶点。在这个观点中,硫基药物和肽基抑制剂都可能阻断 CoV-2-PLpro 催化和/或 Zn 位点中的 Cys 残基,导致 CoV-2-PLpro 功能障碍,从而停止病毒复制。
更新日期:2020-10-11
down
wechat
bug